Cargando…

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome

BACKGROUND: Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is highly selective for EGFR(T790M) subclones in patients with EGFR(sensitizing) non-small cell lung cancer (NSCLC). Unfortunately, all patients develop resistance through EGFR-dependent or EGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vendrell, Julie A., Quantin, Xavier, Aussel, Audrey, Solassol, Isabelle, Serre, Isabelle, Solassol, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674606/ https://www.ncbi.nlm.nih.gov/pubmed/35004240 http://dx.doi.org/10.21037/tlcr-21-679

Ejemplares similares

Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment
por: Vendrell, Julie A., et al.
Publicado: (2020)

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
por: Solassol, Isabelle, et al.
Publicado: (2019)

Case report: Liquid biopsy, the sooner the better?
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
por: Li, Dan, et al.
Publicado: (2021)

ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets
por: Cabello-Aguilar, Simon, et al.
Publicado: (2022)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota
por: Vendrell, Julie A., et al.
Publicado: (2022)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020)

High-throughput detection of clinically targetable alterations using next-generation sequencing
por: Vendrell, Julie A., et al.
Publicado: (2017)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner, Samuel J, et al.
Publicado: (2017)

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
por: Xie, Jianjiang, et al.
Publicado: (2023)

Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management
por: Vendrell, Julie A., et al.
Publicado: (2017)

Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer
por: Yoshinami, Tetsuhiro, et al.
Publicado: (2020)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches
por: Vendrell, Julie A., et al.
Publicado: (2017)

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens
por: Frouin, Eric, et al.
Publicado: (2016)

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma
por: Blateau, Pauline, et al.
Publicado: (2020)

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT
por: Harmand, Pierre-Olivier, et al.
Publicado: (2020)

Use of Autoantibodies to Detect the Onset of Breast Cancer
por: Lacombe, Jérôme, et al.
Publicado: (2014)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third‐generation TKI outcomes
por: Li, Yan, et al.
Publicado: (2020)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
por: Quesada, Stanislas, et al.
Publicado: (2022)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
por: Quesada, Stanislas, et al.
Publicado: (2022)

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma
por: Kim, Taehee, et al.
Publicado: (2019)

Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing
por: Marchant, Julie, et al.
Publicado: (2014)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer
por: Bellanger, Aurélie, et al.
Publicado: (2021)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
por: Pender, Alexandra, et al.
Publicado: (2020)

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
por: Mancini, Maicol, et al.
Publicado: (2021)

Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids
por: Mange, Alain, et al.
Publicado: (2008)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer
por: Vendrell, Julie A., et al.
Publicado: (2019)

Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients
por: Feng, Wei-neng, et al.
Publicado: (2018)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_316a2f8e4u3v3d8qdotup93f44